Neudata research

IQVIA

Visit website

Request report Claim this profile

IQVIA is attending the

[]

About IQVIA

DDQ available

IQVIA (formerly IMS Health and Quintiles) provide analytics, technology solutions, and contract research services to the life sciences industry. They have a vast collection of healthcare data and are often viewed as the gold-standard for pharmaceutical sales data.

IQVIA products

On chain data

New today

Request information

[{"title":"Rx and OTC sales activity","url":"https://www.neudata.co/datasets/rx-and-otc-sales-activity","publication_flag":null},{"title":"MIDAS pharmaceutical sales and Rx counts","url":"https://www.neudata.co/datasets/midas-pharmaceutical-sales-rx-counts","publication_flag":null},{"title":"Drug promotions and prescribing intent","url":"https://www.neudata.co/datasets/drug-promotions-and-prescribing-intent","publication_flag":null},{"title":"Country-level healthcare market forecasts","url":"https://www.neudata.co/datasets/country-level-healthcare-market-forecasts","publication_flag":null},{"title":"Pharmaceutical and prescription counts by diagnosis","url":"https://www.neudata.co/datasets/pharmaceutical-sales-rx-counts-by-diagnoses","publication_flag":null},{"title":"Analytics Link pharma intelligence platform","url":"https://www.neudata.co/datasets/analytics-link-pharma-intelligence-platform","publication_flag":null},{"title":"Pharmaceutical drug pricing insights","url":"https://www.neudata.co/datasets/pharmaceutical-drug-pricing-insights","publication_flag":null}]

Similar vendors to IQVIA

Neudata has identified 37 vendors that have similar offerings to IQVIA. Request the full report to find out more.

Advanced Technologies

Quality Assurance

Essential Supplies

NextGen Services

Innovative Strategies

Synergy Partners

Pioneer Solutions

Urban Developments

Noble Ventures

Visionary Concepts

Elite Marketing

Prime Consulting

Future Tech

Bright Ideas

Dynamic Systems

Global Services

Creative Designs

Smart Logistics

Green Innovations

Tech Solutions

News and intelligence related to IQVIA

[{"title":"Revisiting the healthcare data landscape in 2026","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBckNHIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--e7759ae4d4f31da43ed55cd6aa138bc380b95e2e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/haley-lawrence-HTttz00wkzU-unsplash.jpg","url":"https://www.neudata.co/intelligence/revisiting-the-healthcare-data-landscape-in-2026","publication_date":"2026-01-28","category":"Intelligence"},{"title":"Cures or crashes: Do clinical trial outcomes influence stock prices? ","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdlJiIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--bdb881cb689f1ed1946305359138aacc9e63d3bd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/louis-reed-pwcKF7L4-no-unsplash.jpg","url":"https://www.neudata.co/literature-reviews/cures-or-crashes-do-clinical-trial-outcomes-influence-stock-prices","publication_date":"2025-12-09","category":"Literature Review"},{"title":"What non-healthcare datasets are healthcare investors exploring?","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdlplIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--dcda1aa109c104e085af5a46e0d2dfb8ba87c825/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/national-cancer-institute-NFvdKIhxYlU-unsplash.jpg","url":"https://www.neudata.co/intelligence/what-non-healthcare-datasets-are-healthcare-investors-exploring","publication_date":"2025-08-06","category":"Intelligence"},{"title":"Navigating data for AI training (UPDATED)","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBbXRSIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--6390d1cfe90e8dbb6c6135a5169b8434897d08df/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/ian-battaglia-9drS5E_Rguc-unsplash.jpg","url":"https://www.neudata.co/intelligence/navigating-data-for-ai-training","publication_date":"2024-09-04","category":"Intelligence"},{"title":"Healthcare claims disruptions: What next?","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZ0ZSIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--840394b34a095a942ee137215240a49643591845/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/towfiqu-barbhuiya-w8p9cQDLX7I-unsplash.jpg","url":"https://www.neudata.co/intelligence/healthcare-claims-disruptions-what-next","publication_date":"2024-06-18","category":"Intelligence"},{"title":"Money meets medicine: The private equity prescription for alternative healthcare data","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBc2hLIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--6f0e79dbaa8e95280adccac08cdfa20b2efcf885/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/christine-sandu-jwWtZrm67VI-unsplash.jpg","url":"https://www.neudata.co/intelligence/money-meets-medicine-the-private-equity-prescription-for-alternative-healthcare-data","publication_date":"2024-01-10","category":"Intelligence"},{"title":"Healthcare revisited – A quick 2023 bird’s-eye view","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBc3BLIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--2546ed8339bb6683b746f3e0adc4cec181a8ea4e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZ3pNVEVHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--b55e821fff1fb6a5277a641f9807539f25cc39cc/christina-victoria-craft-ZHys6xN7sUE-unsplash.jpg","url":"https://www.neudata.co/intelligence/healthcare-revisited-a-quick-2023-birds-eye-view","publication_date":"2023-09-27","category":"Intelligence"},{"title":"People Moves (30 Jul): IQVIA, App Annie, PortingXS, 1010data and more","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBcTlFIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--a3ef3bf8c4af36c81485a9e75bc5c3fa493a25c1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/efe-kurnaz-RnCPiXixooY-unsplash.jpg","url":"https://www.neudata.co/alternative-data-news/people-moves-iqvia-app-annie-portingxs-1010data-and-more","publication_date":"2020-07-30","category":"News"},{"title":"COVID-19: 11 ways to assess the healthcare sector","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBbmhMIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--46945be9318f2c641710d00f6300b330a9baa780/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZ3pNVEVHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--b55e821fff1fb6a5277a641f9807539f25cc39cc/covid-19-healthcare-intelligence-header-image.jpg","url":"https://www.neudata.co/intelligence/covid-19-11-ways-to-assess-the-healthcare-sector","publication_date":"2020-04-23","category":"Intelligence"},{"title":"Alternative Data for Healthcare Investors (Part IV): Claims vs EHRs","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBc2RLIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--1a900f49c1104888b3f6d591f057f0b4893191cf/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/part-iv-HEADER.jpg","url":"https://www.neudata.co/intelligence/alternative-data-for-healthcare-investors-part-iv-claims-vs-ehrs","publication_date":"2019-09-12","category":"Intelligence"},{"title":"Alternative Data for Healthcare Investors (Part III): Clinical Trial Datasets","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBc1JLIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--74c18ffd4727d00d4a79028298a612652bead929/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/haley-lawrence-HTttz00wkzU-unsplash.jpg","url":"https://www.neudata.co/intelligence/alternative-data-for-healthcare-investors-part-iii-clinical-trial-datasets","publication_date":"2019-07-11","category":"Intelligence"},{"title":"Alternative Data for Healthcare Investors (Part II): Predicting Clinical Trial Outcomes","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBc05LIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--310850a07118e2dbcaaaa933c9dd0a6d274a1975/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/header-image-partII1.jpg","url":"https://www.neudata.co/intelligence/alternative-data-for-healthcare-investors-part-ii-predicting-clinical-trial-outcomes","publication_date":"2019-04-11","category":"Intelligence"},{"title":"Alternative Data for Healthcare Investors (Part I): A Primer on Real-World Data","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBckpMIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--ee0bcefbb716c95505b7a0536284a57952d7e181/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/header-option-1-aerial-view-application-935869-1.jpg","url":"https://www.neudata.co/intelligence/alternative-data-for-healthcare-investors-part-i-a-primer-on-real-world-data","publication_date":"2019-03-14","category":"Intelligence"},{"title":"Using Alternative Data to Evaluate Pharmaceutical Pipelines","image":"https://www.neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdnRJIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--4983527220116d89125771a1a0d6e5f0addd2a7f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/simone-van-der-koelen-611419-unsplash.jpg","url":"https://www.neudata.co/intelligence/using-alt-data-to-evaluate-pharmaceutical-pipelines","publication_date":"2018-05-23","category":"Intelligence"}]

IQVIA risk check

Dataset type(s) - select all that apply.

Please highlight any of the following components that may be included in your categories selected above (Personal data, location data, demographic data, or other sensitive data elements).

Please list the data products this assessment covers.

Mauris eu cursus odio, sit amet aliquam sem.

How long have you been selling data?

Donec tempor, libero non ultrices volutpat.

Please highlight any relevant litigation or negative press.

Phasellus dolor tellus.

How many financial services firms are using your data (excluding corporate users and unpaid trialists)?

Cras mattis, turpis sit amet volutpat viverra.

Request access

["Transactional"]

About Neudata

Neudata provides unbiased research and expert consultancy on data sources and use cases. We connect data buyers and sellers through our platform, creating efficiencies for people who work with data.

Our platform includes in-depth research on thousands of data vendors, which are evaluated on over 100 unique factors to ensure their usability for data buyers.

Data buyers: Discover, manage, stay ahead

We exist to simplify the complex world of data discovery. By guiding investment teams through sourcing, trialling and managing data, we empower them to focus on what they do best – generating alpha.

Let's get started

Are you IQVIA?

Take control of your Neudata profile to ensure accurate representation of your data offerings and maximise visibility with qualified buyers in the investment space.

Claim your profile

Request a full version of this report

Neudata publishes in-depth research on data vendor products and offerings, including information on pricing and the competitive landscape. Fill out your details below to request a full version of this research report.

Founded

Quintiles was founded in 1982 by Dennis Gillings CBE and IMS Health was founded in 1954 by Ludwig Frohlich. The two companies merged to form IQVIA in 2016.

Company history

IQVIA was formed through the merger of IMS Health, a healthcare data aggregator, and Quintiles, a contract research organisation, in 2016. At this time, the firm was known as QuintilesIMS. In November 2017, the company was renamed as IQVIA and changed its NYSE ticker symbol from Q to IQV.

Office locations

100+ office locations across North America, Asia, Australia & New Zealand, Europe, Latin America, Africa, and the Middle East.

Number of employees

58,000+ (including 21,000+ in Technology & Analytics Solutions)

Sources of funding

IQVIA is publicly listed – the firm trades on the NYSE as IQV and is a component of the S&P 500.

Contact name

John Smith

Contact role

Analyst